Rani Therapeutics Holdings (RANI) Accounts Payables (2020 - 2026)

Rani Therapeutics Holdings has reported Accounts Payables for 7 years, with the latest figure at $1.0 million in Q2 2026.

• On a quarterly basis, Accounts Payables fell 41.66% year-over-year to $1.0 million in Q2 2026; TTM through Jun 2026 was $1.0 million, a 41.66% decrease from a year earlier, with the FY2025 full-year figure at $309000.0, down 77.26% from the prior year.
• Accounts Payables was $1.0 million for Q2 2026 at Rani Therapeutics Holdings, up from $858000.0 in the prior quarter.
• The five-year high for Accounts Payables was $2.5 million in Q3 2025, with the low at $309000.0 in Q4 2025.
• Average Accounts Payables over 5 years is $1.3 million, with a median of $1.4 million recorded in 2023.
• The largest YoY upside for Accounts Payables was 255.34% in 2025 against a maximum downside of 77.26% in 2025.
• Over 5 years, Accounts Payables stood at $1.5 million in 2022, then tumbled by 55.62% to $648000.0 in 2023, then jumped by 109.72% to $1.4 million in 2024, then tumbled by 77.26% to $309000.0 in 2025, then surged by 239.48% to $1.0 million in 2026.
• The last three Accounts Payables figures came in at $1.0 million (Q2 2026), $858000.0 (Q1 2026), and $309000.0 (Q4 2025), per Business Quant data.